A Review of Fragile X Premutation Disorders
- 5 May 2009
- journal article
- review article
- Published by Physicians Postgraduate Press, Inc in The Journal of Clinical Psychiatry
- Vol. 70 (6) , e1-e11
- https://doi.org/10.4088/jcp.08m04476
Abstract
Fragile X premutation conditions are associated with a significant degree of psychopathology and thus are of interest to the psychiatrist. Remarkable advances at the molecular level have enhanced our understanding of fragile X premutation disorders. The authors review the genetic, molecular, neuroimaging, and clinical (systemic, neurologic, and psychiatric) manifestations of the premutation carrier state (55-200 CGG repeats) of the fragile X mental retardation 1 (FMR1) gene. The search for the psychiatric clinical manifestations of fragile X-associated conditions was accomplished by PubMed for clinical papers published between 1970 and 2008 with the following search terms: Fragile X syndrome, depression, psychosis, anxiety, and dementia. Articles addressing psychiatric symptoms in premutation carriers based on review of the abstracts were reviewed. As the majority of the literature on this topic is based on case reports and small case series, these were included in the database. Reported clinical manifestations of psychiatric illness in premutation carriers include an apparently significant rate of cognitive, mood, anxiety, and other psychiatric disorders. Fragile X premutation-associated conditions are part of the clinical differential diagnosis of several psychiatric syndromes, particularly in pedigrees with known fragile X syndrome cases. Fragile X-associated psychiatric manifestations serve as a useful model for a molecular genesis of neuropsychiatric illness. Because of the multigenerational expression of fragile X-associated neuropsychiatric illness, there is a prominent role for genetic testing and genetic counseling of patients and their relatives. Genetic testing is confirmatory of the FMR1 premutation and is an essential component of the clinical evaluation. Psychopharmacologic and psychotherapeutic treatment of fragile X-associated psychiatric illnesses may improve patient function and assist in adaptation to the burden of a genetic neuropsychiatric illness.This publication has 78 references indexed in Scilit:
- Altered hypothalamus–pituitary–adrenal gland axis regulation in the expanded CGG-repeat mouse model for fragile X-associated tremor/ataxia syndromePsychoneuroendocrinology, 2008
- Treatment of fragile X-associated tremor ataxia syndrome (FXTAS) and related neurological problemsClinical Interventions in Aging, 2008
- Expanded clinical phenotype of women with the FMR1 premutationAmerican Journal of Medical Genetics Part A, 2008
- Fragile X-associated tremor/ataxia syndrome—an older face of the fragile X geneNature Clinical Practice Neurology, 2007
- Autism Spectrum Disorders and Attention-Deficit/Hyperactivity Disorder in Boys with the Fragile X PremutationJournal of Developmental & Behavioral Pediatrics, 2006
- Lessons from Fragile X Regarding Neurobiology, Autism, and NeurodegenerationJournal of Developmental & Behavioral Pediatrics, 2006
- Abnormal elevation ofFMR1mRNA is associated with psychological symptoms in individuals with the fragile X premutationAmerican Journal Of Medical Genetics Part B-Neuropsychiatric Genetics, 2005
- Intrafamilial variability in fragile X–associated tremor/ataxia syndromeMovement Disorders, 2005
- Association of FMR1 repeat size with ovarian dysfunctionHuman Reproduction, 2005
- The Fragile-X Premutation: A Maturing PerspectiveAmerican Journal of Human Genetics, 2004